Nail Fungus Onychomycosis Treatment 2026 | Podiatrist

Onychomycosis (fungal nail infection) is an infection of the toenail (and less commonly fingernail) caused by dermatophyte fungi, non-dermatophyte molds, or yeasts -- most commonly Trichophyton rubrum (responsible for approximately 70% of cases) -- that invades the nail plate, nail bed, and nail matrix, causing the nail to become thickened, discolored (yellow-brown-white), brittle, and malodorous; it is the most common nail disorder, affecting 10-12% of the general population, increasing to 20-30% in adults over 70 years of age. Why toenails are the primary target: the toenail environment is ideal for fungal growth: the nail plate creates a warm, dark, humid microenvironment; the nail plate is 25 times thicker than skin, preventing topical antifungal penetration; the slower nail growth rate of toenails (1mm per month, compared to 3mm per month for fingernails) means a complete nail takes 12-18 months to grow out, requiring prolonged treatment; the nail is a poor blood supply target, limiting systemic antifungal delivery to nail tissue; Patterns of nail infection: Distal subungual onychomycosis (DLSO) -- the most common type: infection starts at the free edge of the nail and progresses proximally along the nail bed; the nail becomes yellow-brown with subungual debris and onycholysis (separation of the nail plate from the nail bed); Proximal subungual onychomycosis (PSSO): infection starts at the proximal nail fold and spreads distally; more common in immunocompromised patients (a flag for HIV in otherwise healthy-appearing individuals); White superficial onychomycosis (WSO): infection of the dorsal nail plate surface; appears as white patches; caused by T. mentagrophytes; Total dystrophic onychomycosis: complete nail destruction -- the end-stage of any pattern; Risk factors: tinea pedis (the nail typically infects from the reservoir of athlete's foot on the surrounding skin), age, male sex, peripheral vascular disease, diabetes, immunosuppression, nail trauma, communal bathing areas; Diagnosis: KOH preparation of nail clippings confirms hyphae; fungal culture identifies the species and guides treatment selection; PAS staining of nail biopsy is the most sensitive diagnostic method.

Onychomycosis treatment requires prolonged systemic or topical therapy to penetrate the nail plate and eradicate the infection -- topical treatments are convenient but have lower cure rates and are most appropriate for superficial or early infections, while oral antifungals (particularly terbinafine) produce the highest cure rates for established nail infections; laser treatment is an emerging option with variable evidence. The SCIO criteria for treatment decision: clinical severity (percentage of nail involved), number of nails affected, patient health status, and the causative organism all guide treatment selection. Topical antifungal agents: Ciclopirox 8% nail lacquer (Penlac): applied daily to the affected nail and surrounding skin; cure rates 30-40% at 48 weeks; most appropriate for mild-moderate DLSO involving less than half the nail without matrix involvement; requires 48 weeks of daily application; Efinaconazole 10% solution (Jublia): FDA-approved; applied once daily; mycological cure rates 55-60% in clinical trials; better penetration than ciclopirox; Tavaborole 5% solution (Kerydin): boron-based antifungal with high nail penetration; cure rates 35-40%; Oral antifungal agents (highest cure rates): Terbinafine 250mg daily (the preferred oral agent): the most effective treatment for dermatophyte onychomycosis; mechanism: inhibits fungal squalene epoxidase, is fungicidal; toenail treatment: 12 consecutive weeks (3 months); mycological cure rates: 70-80%; complete cure rates: 35-50%; the drug accumulates in the nail plate and remains active for months after discontinuation; check liver function tests before starting and at 6 weeks in patients with liver risk factors; Itraconazole: pulse dosing (200mg twice daily for 1 week per month) for 3-4 months for toenails; alternative for patients who cannot take terbinafine or for non-dermatophyte mold infections; Fluconazole 150mg weekly: less evidence than terbinafine for onychomycosis but used as an alternative; Laser treatment: diode and Nd:YAG lasers target chromophores in the fungal cell; clinical studies show mycological improvement in 50-70% of patients; not FDA-cleared for onychomycosis cure (only for temporary cosmetic improvement); multiple sessions required (typically 3-4); most appropriate for patients who cannot take oral antifungals; Surgical nail avulsion: removal of the infected nail plate allows direct antifungal contact with the nail bed; used adjunctively with antifungal therapy for severe cases or as a standalone treatment; typically performed with concurrent chemical matrixectomy for permanent nail removal in patients who prefer not to regrow a diseased nail; Recurrence: 25-30% recurrence within 3 years; prevention with topical antifungal powder in shoes, treatment of concurrent tinea pedis, and antifungal nail lacquer maintenance.